'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has declined 3.05% to Rs 979.94 crore. Operating profit margin has jumped from 31.83% to 34.26%, leading to 4.36% rise in operating profit to Rs 335.73 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.02% to 11.84%. Purchase of finished goods cost rose from 21.85% to 23.94%. Employee cost decreased from 15.19% to 14.20%. Other expenses fell from 15.51% to 15.49%.
Other income fell 2.81% to Rs 33.57 crore. PBIDT rose 3.66% to Rs 369.3 crore. Provision for interest rose 88.89% to Rs 0.51 crore. Loan funds rose to Rs 35.71 crore as of 30 September 2025 from Rs 14.79 crore as of 30 September 2024. Inventories rose to Rs 535.93 c...
Pleaselogin & subscribe to view the full report.
More Reports
|
|